If you’re looking for cheap stocks to buy now, you’ve come to the right place. Because the truth is, I’ve made an entire career out of discovering undervalued stocks, buying them on the cheap, then riding them to the top.
A stock can be undervalued for many reasons:
- Poor earnings cause a stock to become oversold, falling below its intrinsic value.
- A private placement priced at a significant discount allows for an opening to buy a stock at a discount. Although these tend to happen rather quickly and require quick and decisive action.
- A stock operating within a burgeoning industry showing significant growth potential but is not being covered, or is simply not being properly valued by the Wall Street elite.
It’s the latter where I’ve made the lion’s share of my biggest winners. Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
Consider Tesla (NASDAQ: TSLA), for instance. While the stock has struggled over the past few years, it made huge gains in the first eleven years, following its IPO.
I had actually been covering the EV sector all the way back in 2006. I was meeting with insiders, battery manufacturers, and even spoke at a number of investment conferences about this new industry that would soon prove to be one of the most disruptive things to happen to the automobile market since the first Model T rolled off the line in 1908.
Of course, I was met with a lot of pushback, and even a fair amount of hate mail. But I stuck to my guns. And I’m glad I did. Those who followed my advice and bought shares of Tesla right after it went public made a fortune. Before the stock started selling off, some were up in excess of 19,000%. That’s not a misprint.
A similar thing happened when I started singing the praises of the legal cannabis industry. An industry that really hadn’t received much coverage at all, despite a legalization movement that was taking hold in Canada.
I discovered this movement after a trip to Toronto to visit an old colleague. He made his fortune in the fracking boom, and then expanded that fortune after taking part in a couple of early pre-IPO rounds for a handful of Canadian cannabis stocks.
So I did a bit of digging and realized something very big was about to happen. I extended my trip in Canada, visited a couple of cannabis growing operations, and met with a few lawmakers who had the inside scoop on a new legalization bill.
It was clear to me that Canada would soon legalize the recreational use of cannabis, and I was certain that such an event would send these stocks — which were really penny stocks at the time — to the moon.
I recommended to my readers that they buy shares of three cannabis stocks:
- Aphria, Inc. (TSX: APH)
- OrganiGram Holdings (TSX-V:OGI)
- Canopy Growth Corporation (TSX-WEED)
All three absolutely crushed it. We landed a 1,174% gain on Aphria, a 1,185% gain on OrganiGram, and a 3,015% gain on Canopy Growth Corporation.
To put this in perspective, a one-time investment of $10,000 in Canopy Growth turned into $311,500 in less than three years. That’s more than a quarter of a million dollars. From one single undervalued and super cheap stock.
Now I’m not writing to you today just to chest pound. Instead, I’m writing to you to let you know that I have a new opportunity for you to get in on a few deals that I believe will deliver the same types of gains we saw from Tesla and Canopy Growth Corporation.
More Cheap Stocks to Buy Now
Last month, I told you about something called EN-23.
EN-23 represents a valuable class of molecules that drastically improves brain function. It’s actually one of the biggest breakthroughs medical science has seen in 50 years. Not only can it treat mental health conditions such as depression, anxiety, PTSD and addiction, it also has the ability to help you lose weight, treat chronic pain and even extend your lifespan by up to 20 years.
The profit potential of EN-23 is massive. But similar to what we saw with cannabis, most EN-23 medications are not approved by the government. So naturally, institutional money has largely ignored it. Until now.
You see, on August 11th, we expect the very first EN-23 medication to be approved by the FDA. We got word on this last month. And shortly after that announcement, we discovered that J.P. Morgan (the behemoth investment bank with assets valued in excess of $2.5 trillion), had decided to start meeting with a number of companies developing new EN-23 treatments for mental health conditions.
Since then, the value of my three favorite EN-23 stocks has soared.
I already told you about one of them: MindMed (NASDAQ: MNMD). Here’s how that stock has performed over the past six months …
But mark my words: once the FDA approves the first EN-23 medication sold in the U.S., these other EN-23 stocks are going to the moon. Which is why I put together this new investment report on my favorite EN-23 Stocks to buy before August 11th.
These ARE undervalued stocks. They are, without a doubt, the next cheap stocks to buy now. So unless you hate money, I highly recommend you get some of this action for yourself.
While I may not always be the smartest person in the room, I know how to find — and profit from — undervalued stocks. And those who follow my advice tend to make a lot of money in the process. If you don’t believe me, just look at the numbers for yourself To a new way of life and a new generation of wealth… Jeff Siegel
@JeffSiegel on Twitter
Check us out on YouTube!Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.
